Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Allogene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Allogene Therapeutics's regulatory disclosures and financial reporting.
Allogene Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders and related corporate actions. Stockholders elected three Class II directors to serve until the 2029 annual meeting and approved, on an advisory basis, the compensation of named executive officers and an annual say-on-pay vote.
Stockholders also approved an amendment to increase authorized common shares from 400,000,000 to 800,000,000, which became effective on June 18, 2026. They ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026. Separately, the company filed a prospectus supplement covering sales of common stock with an aggregate offering price of up to $135.0 million under an existing Sales Agreement with TD Securities (U.S.A.) LLC.
Allogene Therapeutics filed a prospectus supplement to sell up to $135,000,000 of common stock through an at‑the‑market program with TD Securities (USA) LLC (TD Cowen) as sales agent. Sales may occur from time to time at market prices and TD Cowen’s commission is up to 3.0% of gross proceeds. The supplement references a last reported sale price of $2.00 per share on June 18, 2026 and states proceeds will be used for general corporate purposes, including clinical trials, R&D, G&A and capital expenditures. The company also amended its charter to increase authorized common shares to 800,000,000.
Allogene Therapeutics announced that its Board appointed Zachary Roberts, M.D., Ph.D. as President and Chief Executive Officer, succeeding David Chang, M.D., Ph.D. effective July 1, 2026. Dr. Chang’s last day as President and CEO will be June 30, 2026, after which he will remain on the Board as a non-employee director.
On the Effective Date, Dr. Roberts will also join the Board as a Class I director, serving until the 2028 annual meeting or until a successor is elected and qualified. He currently serves as Executive Vice President, Research and Development, and Chief Medical Officer, and will continue as Chief Medical Officer on an interim basis.
His new compensation includes an annualized base salary of $680,000, an annual target cash incentive of 60% of base salary, an option to purchase 476,190 shares, and a restricted stock unit award of 134,530 shares, all subject to service-based vesting. Both Dr. Roberts and Dr. Chang are entitled to severance and change in control benefits under the company’s existing Severance Plan as described in its April 30, 2026 proxy statement.
Allogene Therapeutics joint Schedule 13G/A discloses that Citadel-related entities and Kenneth Griffin report shared beneficial ownership positions in the issuer's common stock. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each report 5,795,242 shares (2.4%). Citadel Securities LLC reports 614,069 shares (0.3%). Citadel Securities Group LP and Citadel Securities GP LLC each report 1,059,878 shares (0.4%). Kenneth Griffin is reported as beneficially owning 6,855,120 shares (2.8%). The filing cites 243,777,920 Shares outstanding as of March 10, 2026 per the issuer's Form 10-K.
Allogene Therapeutics — Amendment No. 1 to a Schedule 13G/A was filed by Lynx1 Capital Management LP and Weston Nichols reporting 0 shares beneficially owned, representing 0% of the outstanding common stock as shown on the cover page. The filing states Ownership of 5 percent or less of a class and is signed by Weston Nichols on 05/15/2026.
Allogene Therapeutics amendment to a Schedule 13G/A reports beneficial ownership by Arie Belldegrun and affiliated entities of 13,466,383 shares of Common Stock, representing 5.4% of the class. The filing states 243,777,920 shares outstanding as of March 10, 2026. The cover page shows 3,866,329 shares issuable upon exercise of options within 60 days of March 31, 2026.
Allogene Therapeutics ownership update: David D. Chang and affiliated trusts report beneficial ownership of 12,297,354 shares of common stock, representing 4.9% of the class. The filing states 243,777,920 shares outstanding as of March 10, 2026.
The cover-page detail shows 6,345,007 shares exercisable within 60 days of March 31, 2026 (stock options held by Dr. Chang). Trust holdings listed include Chang 2006 Family Trust 1,201,108 shares, JEC 2019 Trust 856,044 shares, and RTC 2019 Trust 856,044 shares.
Allogene Therapeutics, Inc. reported a net loss of $42.6 million for the quarter ended March 31, 2026, improving from $59.7 million a year earlier as total operating expenses fell to $46.1 million from $65.2 million.
Cash, cash equivalents and investments totaled $266.9 million at quarter‑end, before an additional $187.9 million in net proceeds from an April 2026 equity offering of 100.2 million shares at $2.00 per share. The company now expects its cash resources to fund operations into the first quarter of 2029.
Allogene continues to focus on three core programs: the pivotal ALPHA3 trial of cema‑cel in first‑line large B‑cell lymphoma, the TRAVERSE study of ALLO‑316 in renal cell carcinoma, and the RESOLUTION basket trial of ALLO‑329 in autoimmune diseases, all supported by its Dagger® platform and multiple external collaborations.
Allogene Therapeutics reported first quarter 2026 results and a major portfolio change. The company terminated its exclusive license with Overland covering four CAR T targets in parts of Asia, with no termination payments, and restructured its Overland ownership and governance; Allogene now expects to hold about 3% of Overland’s equity.
Interim data from the pivotal Phase 2 ALPHA3 trial showed 58.3% of patients on cemacabtagene ansegedleucel achieved minimal residual disease clearance versus 16.7% on observation, with a 97.7% median ctDNA reduction and no CRS, ICANS, GvHD, treatment-related serious events or hospitalizations. In autoimmune disease, nine patients have been treated in the Phase 1 RESOLUTION trial of ALLO-329 with early signs of activity and favorable tolerability.
Research and development expense was $32.0 million and general and administrative expense was $14.1 million, leading to a net loss of $42.6 million, or $0.18 per share. Allogene ended the quarter with $266.9 million in cash, cash equivalents and investments, and an April 2026 public offering added $200.4 million in gross proceeds, extending projected cash runway into the first quarter of 2029. The company now guides 2026 operating cash expense to about $165 million and GAAP operating expenses to about $225 million.